Clinical Trial

SKB500 Combinations in Patients With Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-03
Trial Details
NCT Number NCT07296809
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Small Cell Lung Cancer
Enrollment 80 participants
Start Date 2026-01-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08